Ohman K P, Yun J C, Keiser H R
Hypertension-Endocrine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD.
Scand J Clin Lab Invest. 1992 Oct;52(6):483-90. doi: 10.3109/00365519209090125.
The interaction of prostaglandins with changes in cytosolic Ca2+ concentration ([Ca2+]) and aggregation of human platelets induced by adenosine diphosphate (ADP) were investigated. Cytosolic [Ca2+] was measured with the fluorescent dye Quin2. Addition of ADP (0.25-2.5 mumol l-1) to platelet suspensions produced a dose dependent increase in cytosolic [Ca2+] from a basal level of 51 +/- 1 nmol l-1 to maximum levels exceeding 1 mumol l-1 and induced platelet aggregation. Chelation of extracellular calcium with 100 mumol l-1 EGTA markedly reduced the increase in cytosolic [Ca2+] induced by 0.25 mumol l-1 ADP, while pretreatment with the calcium entry blocker verapamil was without effect. Stimulation of cyclic AMP with prostaglandins (PGD2, PGE1, PGE2, PGI2, but not PGF2 alpha) and forskolin, or incubation with dibutyryl-cAMP, inhibited the rise in cytosolic [Ca2+] and platelet aggregation following ADP. We conclude that prostaglandins inhibit the increase in cytosolic [Ca2+] and aggregation of human platelets induced by ADP, probably by stimulation of cyclic AMP generation, thereby opposing the mechanism by which ADP increases cytosolic [Ca2+] and subsequently induces platelet aggregation.
研究了前列腺素与胞质Ca2+浓度([Ca2+])变化以及二磷酸腺苷(ADP)诱导的人血小板聚集之间的相互作用。用荧光染料喹哪啶红测量胞质[Ca2+]。向血小板悬液中添加ADP(0.25 - 2.5 μmol l-1)会使胞质[Ca2+]从基础水平51±1 nmol l-1呈剂量依赖性增加至超过1 μmol l-1的最大水平,并诱导血小板聚集。用100 μmol l-1乙二醇双乙醚二胺四乙酸(EGTA)螯合细胞外钙可显著降低0.25 μmol l-1 ADP诱导的胞质[Ca2+]增加,而用钙通道阻滞剂维拉帕米预处理则无效。用前列腺素(PGD2、PGE1、PGE2、PGI2,但不包括PGF2α)和福斯高林刺激环磷酸腺苷(cAMP),或用二丁酰-cAMP孵育,可抑制ADP作用后胞质[Ca2+]的升高和血小板聚集。我们得出结论,前列腺素可能通过刺激cAMP生成来抑制ADP诱导的人血小板胞质[Ca2+]增加和聚集,从而对抗ADP增加胞质[Ca2+]并随后诱导血小板聚集的机制。